Biodexa Pharmaceuticals Prices Public Offering at $3.28
Biodexa Pharmaceuticals announced the pricing of a best efforts public offering of an aggregate of 157,000 units, with each unit consisting of one American depositary share, and two Series L warrants, each to purchase one ADS , and 2,891,781 pre-funded units, with each Pre-Funded Unit consisting of one pre-funded warrant to purchase one ADS and two Series L Warrants. The combined public offering price of each ADS Unit is $3.28, and the combined public offering price of each Pre-Funded Unit is $3.2799. The securities comprising the Units are immediately separable and will be issued separately. Each Series L Warrant will expire on the five-year anniversary of the date of issuance and will be immediately exercisable upon issuance at an exercise price of $3.28 per ADS. The aggregate gross proceeds to the Company, before deducting placement agent fees and other offering expenses, are expected to be approximately $10M. The Company intends to use the net proceeds from this offering to fund its development programs, for working capital and for other general corporate purposes. The offering is expected to close on December 19, 2025, subject to the satisfaction of customary closing conditions. Maxim Group is acting as the sole placement agent in connection with the offering.
Get Free Real-Time Notifications for Any Stock
Analyst Views on BDRX
About BDRX
About the author
Biodexa Pharmaceuticals Appoints Fiona Sharp as CFO, Shares Rise 3.45%
- Executive Transition: Biodexa Pharmaceuticals has promoted Fiona Sharp to Chief Financial Officer and Company Secretary, effective immediately, aiming to strengthen financial management and enhance operational efficiency within the company.
- Succession Plan: Sharp succeeds Stephen Stamp, who will continue as Chief Executive Officer, ensuring stability and continuity in the company's leadership during this transition.
- Financial Expertise: Having served as Group Financial Controller since December 2019, Sharp brings extensive financial management experience, previously holding the position of Assistant Director of Finance at Hywel Dda University Health Board, which is expected to enhance the company's financial strategy.
- Market Reaction: BDRX shares are currently trading at $2.54, reflecting a 3.45% increase from the previous trading day, indicating positive market sentiment regarding the new CFO's appointment and confidence in the company's future growth prospects.
B. Riley Financial Shares Surge Approximately 25%; Check Out 20 Stocks Making Moves in Premarket Trading
B. Riley Financial Performance: B. Riley Financial Inc reported a significant turnaround with earnings of $4.50 per share for Q2, compared to a loss of $14.35 per share a year ago, and sales increased to $225.302 million from $94.885 million, leading to a 25% rise in share price during pre-market trading.
Pre-Market Stock Movements: Several stocks experienced notable pre-market trading movements, with Biodexa Pharmaceuticals gaining 51.4% and Venus Concept surging 31.1%, while Radiopharm Theranostics saw a sharp decline of 39.8%.
Other Notable Gainers: Other stocks that rose in pre-market trading included Uniqure NV (+14.1%), Adagio Medical Holdings (+11.7%), and Sunrise New Energy (+10.5%), reflecting a mix of recovery and growth in various sectors.
Significant Losers: Stocks that faced declines included iRobot Corp, which fell 23.2% after filing for Chapter 11 bankruptcy, and Saverone 2014 Ltd, which tumbled 37.8% following a previous gain, indicating volatility in the market.
